Biopharmaceutical industry leaders got the chance to present some truly innovative work at this yearâ€™s CPhI North America and BIO International conferences on the BioProcess International Theater stages.
In this monthâ€™s Featured Report, BioProcess International gathers key insights from the presentations delivered at CPhIâ€™s and BIOâ€™s installments of the BPI Theater. This digital edition also features access to online archives with recordings of each presentation.Â Follow the links below to learn more about the exciting range of discussions.
CPhI North America 2019
CPhI North America and BPI joined forces in Chicago last spring to present the 2019 BioProcess International Theater. Speakers and attendees converged on the McCormickâ€™s Place main exhibition hall on April 30th and May 1st to explore four key themes:
- Business strategies for a maturing industry
- Mapping new pathways from discovery to development
- Manufacturing strategies
- Identifying and implementing tools for process optimization.
In their individual presentations as well as the larger panel discussions, which were moderated by BioProcess Insider editor and cofounder Dan Stanton, representatives from industry suppliers paid special attention to the challenges of developing bioconjugates, the potential for manufacturing bottlenecks, and strategies for overcoming those production challenges.
BIO International 2019
BPI Theater presentations at the BIO event, held in Philadelphia between June 3rd and 6th, took up more directly the idea of innovation.Â Presentations centered their remarks around:
- Emerging Therapies
- Antibodyâ€“drug conjugates (ADCs)
- CAR-T treatments
- Monoclonal antibodies (MAbs)
- Viral vectors
- Emerging Techniques, Technologies, and Tools
- Multicolumn chromatography techniques
- Protein expression systems
- Sensor systems
- Gene library platforms
In addition to conventional individual presentations and panel discussions, June 4th and 5th featured face-to-face interviews between Stanton and executives from industry-leading process sponsors, manufacturers, and consultants.
Speakers at BIO highlighted how industry suppliers are responding to both challenges and opportunities relating to manufacturing capacity, particularly where it concerns expressing and mass-producing novel proteins. Presenters also reflected on how far the biopharmaceutical industry has come and where it can go in the age of individualized cell and gene therapies.